ProCE Banner Activity

ESPAC-4: Adjuvant Gemcitabine/Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma

Slideset Download
Conference Coverage
Survival benefit was consistent across prognostic criteria of grade, disease stage, lymph node involvement, and resection margins, and there was no significant difference in treatment-related serious adverse events between the 2 treatment arms.

Released: June 14, 2016

Expiration: June 13, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals